Neurotrophic Effect of a Novel TrkB Agonist on Retinal Ganglion Cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE: Retinal ganglion cells (RGCs) die in glaucoma and virtually all optic neuropathies. Recently, novel tropomyosin-related kinase B (TrkB) monoclonal antibodies have been shown to activate TrkB receptors and exert neuroprotective and neurotrophic effects. In the present study, the authors examined the ability of one of them, 29D7, to elicit RGC survival and neurite growth both in culture and in vivo. METHODS: RGCs from postnatal day (P)3 to P4 Sprague-Dawley rats were isolated by sequential immunopanning using a monoclonal antibody to Thy1. RGCs were cultured in serum-free defined medium in 96-well plates. RGC viability was assessed after 1 to 3 days by MTT assay. Activation of TrkB and downstream signaling molecules was confirmed by Western blot analysis. Intravitreal injections of 29D7 were performed after optic nerve axotomy, and subsequent RGC survival was quantified using beta-III tubulin immunostaining. Regeneration was assessed using retrograde fluorogold tracing in an optic nerve-peripheral nerve graft model. RESULTS: Similar to brain-derived neurotrophic factor (BDNF), the 29D7 antibody strongly promoted RGC survival and neurite growth in vitro compared with medium alone or control IgG. Forskolin, which weakly supported RGC survival on its own, potentiated the effect of 29D7. Intravitreal injection of 29D7 enhanced RGC survival but not regeneration in vivo 2 weeks after optic nerve injury. CONCLUSIONS: Together, these findings demonstrate the potential for antibody-mediated TrkB agonism as a potential therapeutic approach to enhance RGC survival after optic nerve injury. Further studies are needed to elucidate the mechanistic differences between this TrkB agonist and BDNF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway
Park, K. K., Liu, K., Hu, Y., Smith, P. D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I., Sahin, M., et al. (2008) · Science · doi:10.1126/science.1161566 · Cited by 1,686
Self-citationNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Nadal-Nicola´s, F. M., Jime´nez-Lo´pez, M., Sobrado-Calvo, P., Nieto-Lo´pez, L., Ca´novas-Marti´nez, I., Salinas-Navarro, M., Vidal-Sanz, M., & Agudo, M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3267 · Cited by 541
Depolarization and cAMP Elevation Rapidly Recruit TrkB to the Plasma Membrane of CNS Neurons
Meyer-Franke, A., Wilkinson, G. A., Kruttgen, A., Hu, M., Munro, E., Hanson, M. G., Reichardt, L. F., & Barres, B. A. (1998) · Neuron · doi:10.1016/s0896-6273(00)80586-3 · Cited by 516
Chen, H., & Weber, A. J. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.024 · Cited by 75
Qian, M. D., Zhang, J., Tan, X.-Y., Wood, A., Gill, D., & Cho, S. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1118-06.2006 · Cited by 67 · cited 4×
“29D7 can activate proximal and secondary signaling molecules downstream of TrkB receptors in cell lines.(14) We next asked whether 29D7 similarly activates these pathways in purified, primary RGCs treated with NB (control) medium, control IgG (10 g/mL), 29D7 (10 g/mL), or BDNF (50 ng/mL).”
BackgroundResultInfluentialSelf-citation
Cited by
The molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“TrkB agonists are showing positive results in promoting RGC survival in acute and chronic models of glaucoma (Bai et al., 2010; Hu et al., 2010).”
Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1041-8 · Cited by 175
Tejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
“7,8-DHF acts as a selective and efficient TrkB agonist and presents neuroprotective effects in excitotoxic processes induced in vitro [199] or using in vivo models of brain ischemia [198], AD [200], ALS [201] or PD [198], among others.”
BackgroundKim, G. S., Cho, S., Nelson, J. W., Zipfel, G. J., & Han, B. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088962 · Cited by 27
“Further insights into the ERK1/2 downstream mediators that are required for protection against injury in vivo seem warranted to attempt to elucidate the molecular mechanism underlying neuroprotective action of 29D7 [59,60].”
BackgroundSelf-citation
Metadata
- Authors
- Hu, Y., Cho, S., & Goldberg, J. L.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 1747
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1993451440
- Cited by
- 75
- References
- 6
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.